Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma’s Blame-The-Middleman Strategy Pays Off – For Now

Executive Summary

Success of drug industry’s campaign to highlight role of 'middlemen' in the supply chain was never more clear than during President Trump’s Rose Garden drug pricing event. But what happens now that the attention is turned squarely back on manufacturers?


Related Content

PCMA’s Merritt Reflects On 15 Years At The Helm Of PBM Advocacy
PBMs’ Impact On Drug Prices Probed By House Committee Leaders
Novartis And Cohen: A View Into Pharma's Policy Concerns As Trump Took Office
Pricing Positives From Trump Plan Include Potential 340B Changes, Value-Based Contracts
Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
Opioid Manufacturers Should Prepare For A Tobacco Moment
Breaking 340B: What Happens After Medicare Payment Cut?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts